

Resource Summary Report

Generated by [dkNET](#) on Jul 29, 2026

ATCC

RRID:SCR_001672

Type: Tool

Proper Citation

ATCC (RRID:SCR_001672)

Resource Information

URL: <http://www.atcc.org/>

Proper Citation: ATCC (RRID:SCR_001672)

Description: Global nonprofit biological resource center (BRC) and research organization that provides biological products, technical services and educational programs to private industry, government and academic organizations. Its mission is to acquire, authenticate, preserve, develop and distribute biological materials, information, technology, intellectual property and standards for the advancement and application of scientific knowledge. The primary purpose of ATCC is to use its resources and experience as a BRC to become the world leader in standard biological reference materials management, intellectual property resource management and translational research as applied to biomaterial development, standardization and certification. ATCC characterizes cell lines, bacteria, viruses, fungi and protozoa, as well as develops and evaluates assays and techniques for validating research resources and preserving and distributing biological materials to the public and private sector research communities.

Abbreviations: ATCC

Synonyms: ATCC: The Global Bioresource Center, American Type Culture Collection, ATCC(dna), ATCC(in host)

Resource Type: commercial organization

Keywords: biomaterial, cell line, culture, microorganism, proteomics, protozoa, tissue, bacteria, virus, fungus, standardization, molecular genomics, reagent, yeast, microbial culture, stem cell, dna, FASEB list

Availability: Free, Freely Available

Resource Name: ATCC

Resource ID: SCR_001672

Alternate IDs: ISNI: 0000 0001 2161 7948, Wikidata: Q2843042, grid.281196.5, nif-0000-10159

Alternate URLs: <https://ror.org/03thhhv76>

Record Creation Time: 20220129T080208+0000

Record Last Update: 20260725T190506+0000

Ratings and Alerts

No rating or validation information has been found for ATCC.

No alerts have been found for ATCC.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 106406 mentions in open access literature.

Listed below are recent publications. The full list is available at [dkNET](#) .

Huang M, et al. (2026) KRT81 promotes metastasis of colorectal cancer by acting as a protein scaffold for ezrin. *Oncogene*, 45(3), 459.

Lv X, et al. (2026) Blautia coccoides-derived metabolite trimethylamine-N-oxide exacerbates Alzheimer's disease progression via targeting HIF1 α signaling. *Gut microbes*, 18(1), 2605768.

Clevenger AJ, et al. (2025) Oncogenic KRAS Mutations Confer a Unique Mechanotransduction Response to Peristalsis in Colorectal Cancer Cells. *Molecular cancer research : MCR*, 23(2), 128.

Onecha VV, et al. (2025) Space- and Time-Defined Monte Carlo Dosimetry Explains Ovarian Cancer Cell Viability in Targeted α -Particle Therapy With Astatine 211-ParaThanatrace. *International journal of radiation oncology, biology, physics*.

Lazana I, et al. (2025) Use of a Foamy-Virus Vector System to Produce an 'Off-the-Shelf' Fc γ -CR-T Cell Product for the Treatment of Haematological and Solid Tumour Malignancies. *Immunology*, 176(4), 520.

Maeoka R, et al. (2025) Immunotherapy using allogenic NK cells downregulates mitochondrial-related genes and inhibits the OXPHOS system of malignant meningioma. *Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie*, 187, 118099.

VandenHeuvel SN, et al. (2025) Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis. *Advanced*

healthcare materials, e01791.

Ray P, et al. (2025) SMURF2 Facilitates GAP17 Isoform 1 Membrane Displacement to Promote Mutant p53-KRAS Oncogenic Synergy. *Molecular cancer research : MCR*, 23(6), 530.

Bhagwat SV, et al. (2025) Imlunestrant Is an Oral, Brain-Penetrant Selective Estrogen Receptor Degradar with Potent Antitumor Activity in ESR1 Wild-Type and Mutant Breast Cancer. *Cancer research*, 85(4), 777.

Valvo VM, et al. (2025) Olaparib and Radiotherapy Induce Type I Interferon- and CD8+ T Cell-Dependent Sensitization to Immunotherapy in Pancreatic Cancer. *Molecular cancer therapeutics*, 24(6), 843.

Lafargue A, et al. (2025) Twist1-induced suppression of oncogene-induced senescence in non-small cell lung cancer requires the transactivation domain of Twist1. *Neoplasia (New York, N.Y.)*, 66, 101179.

Badal S, et al. (2025) Novel Afro-Caribbean Prostate Cancer Model Reveals Ancestry-Specific Drug Vulnerabilities with Therapeutic Implications for Black Patients. *Cancer research communications*, 5(10), 1758.

Wang R, et al. (2025) Anti-mitotic agent SB-216 overcomes taxane resistance in castration-resistant prostate cancer and exhibits anti-tumour efficacy in pancreatic cancer. *British journal of pharmacology*.

Faliti CE, et al. (2025) Disease-associated B cells and immune endotypes shape adaptive immune responses to SARS-CoV-2 mRNA vaccination in human SLE. *Nature immunology*, 26(1), 131.

Bergamasco MI, et al. (2025) KAT6B is required for histone 3 lysine 9 acetylation and SOX gene expression in the developing brain. *Life science alliance*, 8(2).

Liu W, et al. (2025) RIPK2 and lysosomal pathway: Unveiling a new mechanism for lung cancer metastasis. *Translational oncology*, 51, 102182.

Chen X, et al. (2025) Nanoformulation of Polymyxin E Through Complex Coacervation: A Pharmacokinetic Analysis. *Pharmaceutics*, 17(1).

Mansor MH, et al. (2025) Efficient and Rapid Microfluidics Production of Bio-Inspired Nanoparticles Derived from Bombyx mori Silkworm for Enhanced Breast Cancer Treatment. *Pharmaceutics*, 17(1).

de Araujo Fernandes AG, et al. (2025) [99mTc]Technetium and Rhenium Dithiocarbamate Complexes: Chemical Synthesis and Biological Assessment. *Pharmaceutics*, 17(1).

Bai S, et al. (2025) Enhanced Immunogenicity and Affinity with A35R-Fc-Based Chimeric Protein Compared to MPXV A35R Protein. *Viruses*, 17(1).